Professor of Medicine, UCSD
Hematology
Dr. Thomas J. Kipps, MD
|
|
Give Review
Thomas Kipps practices Hematology. He graduated from Harvard Medical School. Harvard Medical School is a top medical college. Harvard Medical School has a rank of 1 in research and a 12 in primary care He received awards:"America's Top Doctors", "Top Doctors:San Diego Area", "America's Top Doctors for Cancer", "Top Doctors:Southern California", "CMS Meaningful Use Stage 1 Certification", "Elected Member" and "Super Doctor". Thomas J. Kipps, MD is a published doctor as well. He has 101 publications published. The latest was: Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Dr. Thomas J. Kipps is registered with Medicare.
Publications
- Transcriptome Sequencing Reveals Potential Mechanism of Cryptic 3' Splice Site Selection in SF3B1-mutated Cancers.
- Obinutuzumab (G) plus fludarabine/cyclophosphamide (G-FC) or bendamustine (G-B) in the initial therapy of CLL patients: the phase 1b GALTON trial.
- Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic Leukemia.
- Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic Leukemia: final results from a pivotal study.
- Final results of EFC6663: A multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic Leukemia.
- Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.
- A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic Leukemia.
- Intratumoral Injection of Ad-ISF35 (Chimeric CD154) Breaks Tolerance and Induces Lymphoma Tumor Regression.
- Lenalidomide inhibits the proliferation of chronic lymphocytic Leukemia cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53.
- MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic Leukemia.
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia.
- Translocation t(2;11) in CLL cells results in CXCR4/MAML2 fusion oncogene.
- Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic Leukemia.
- Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphoc...
- MicroRNA-150 contributes to the proficiency of B-cell receptor signaling in chronic lymphocytic Leukemia by regulating expression of GAB1 and FOXP1 genes.
- Dielectrophoretic isolation and detection of cancer related circulating cell free dna biomarkers from blood and plasma.
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia.
- Prolonged Lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
- ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
- Stabilized Cyclopropane Analogs of the Splicing Inhibitor FD-895.
- The Pathogenesis of Chronic Lymphocytic Leukemia.
- MicroRNAs and B cell receptor signaling in chronic lymphocytic Leukemia.
- Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic Leukemia.
- Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Synd...
- A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Trisomy 12 CLLs progress through NOTCH1 mutations.
- Targeting chronic lymphocytic Leukemia cells with a humanized monoclonal antibody specific for CD44.
- Impact of oxygen concentration on growth of mesenchymal stromal cells from the marrow of patients with chronic lymphocytic Leukemia.
- Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood.
- Heat shock protein 70 regulates Tcl1 expression in Leukemia and lymphomas.
- Subclonal evolution involving SF3B1 mutations in chronic lymphocytic Leukemia.
- The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers.
- The down-regulation of miR-125b in chronic lymphocytic Leukemias leads to metabolic adaptation of cells to a transformed state.
- Increased aldehyde dehydrogenase activity in high-risk chronic lymphocytic Leukemia.
- Subnetwork-based analysis of chronic lymphocytic Leukemia identifies pathways that associate with disease progression.
- Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic Leukemia (CLL).
- Gene immunotherapy of chronic lymphocytic Leukemia: a Phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule.
- Recombinant antibodies encoded by IGHV1-69 react with pUL32, a phosphoprotein of cytomegalovirus and B-cell superantigen.
- Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic Leukemia.
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease.
- NOTCH1 mutations in CLL associated with trisomy 12.
- Tcl1 interacts with Atm and enhances NF-kB activation in hematological malignancies.
- Sorafenib-induced apoptosis of chronic lymphocytic Leukemia cells is associated with downregulation of RAF and Mcl-1.
- Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic Leukemia cells.
- ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B Acute lymphoblastic leukemia.
- Rituximab in chronic lymphocytic Leukemia.
- MiR-181b is a biomarker of disease progression in chronic lymphocytic Leukemia.
- Analyses of Recombinant Stereotypic IGHV3-21-Encoded Antibodies Expressed in Chronic Lymphocytic Leukemia.
- Chemoimmunotherapy with ofatumumab, fludarabine, and cyclophosphamide (O-FC) in previously untreated patients with chronic lymphocytic Leukemia.
- CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic Leukemia.
- Chronic lymphocytic Leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
- Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic Leukemia.
- Standardization of fluorescence in situ hybridization studies on chronic lymphocytic Leukemia (CLL) blood and marrow cells by the CLL Research Consortium.
- Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic Leukemia.
- B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic Leukemia.
- microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.
- Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of Leukemia: report from the International Microarray Innovations...
- Reprogramming of miRNA networks in cancer and Leukemia.
- Chemical biology strategy reveals pathway-selective inhibitor of NF-kappaB activation induced by protein kinase C.
- Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic Leukemia.
- Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic Leukemia through phosphoproteomics analysis.
- Systemic mastocytosis in association with chronic lymphocytic Leukemia and plasma cell myeloma.
- Chronic lymphocytic Leukemia of Emu-TCL1 transgenic mice undergoes rapid cell turnover that can be offset by extrinsic CD257 to accelerate disease progression.
- Karyotype-specific microRNA signature in chronic lymphocytic Leukemia.
- Tumor suppression by phospholipase C-beta3 via SHP-1-mediated dephosphorylation of Stat5.
- Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic Leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR...
- Ethacrynic acid exhibits selective toxicity to chronic lymphocytic Leukemia cells by inhibition of the Wnt/beta-catenin pathway.
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic Leukemia.
- Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic Leukemia.
- Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic Leukemia.
- Genomic complexity in chronic lymphocytic Leukemia.
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic Leukemia.
- Use of IGHV3-21 in chronic lymphocytic Leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection.
- MiR-15a and miR-16-1 cluster functions in human Leukemia.
- Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic Leukemia B cells is predicated on the heavy chain CDR3.
- ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic Leukemia.
- Antisera induced by infusions of autologous Ad-CD154-Leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.
- Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory Chronic lymph...
- Value of computed tomography in the monitoring of patients with chronic lymphocytic Leukemia.
- A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic Leukemia.
- Cellular immune therapy for chronic lymphocytic Leukemia.
- Ultraconserved regions encoding ncRNAs are altered in human Leukemias and carcinomas.
- Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic Leukemia.
- Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic Leukemia.
- BAFF and APRIL support chronic lymphocytic Leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
- CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic Leukemia cells lacking functional p53.
- Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic Leukemia.
- CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment.
- CD154 gene therapy for human B-cell malignancies.
- A MicroRNA signature associated with prognosis and progression in chronic lymphocytic Leukemia.
- ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in Chronic lymph...
- miR-15 and miR-16 induce apoptosis by targeting BCL2.
- Novel immune-based treatment strategies for chronic lymphocytic Leukemia.
- Inhibitors of XIAP sensitize CD40-activated chronic lymphocytic Leukemia cells to CD95-mediated apoptosis.
- Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in Chronic lymphocytic leu...
- Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic Leukemia cells via a paracrine pathway distinct from that of SDF-1alpha.
- TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic Leukemia.
- Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic Leukemia B cells.
- ZAP-70 directly enhances IgM signaling in chronic lymphocytic Leukemia.
- Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines.
Schools
Harvard Medical School
Stanford University Med Center
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Cryoglobulinemia
- View All
Doctors Specialties
- Hematology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Power Select HMO
- Blue Card PPO
- CaliforniaCare HMO
- Advantage Preferred DirectAccess Plus PPO
- Blue Cross Blue Shield of California PPO
- Pathway X Direct Access PPO
- Pathway X Tiered Direct Access
- Select Plus HMO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- GEHA
- Medicare Advantage PFFS
- HealthSmart
- Humana
- Kaiser Permanente
- Medicaid
- Medicare MCR
- Kaiser PHCS Network PPO
- MultiPlan PPO
- PHCS Network PPO
- Optima Health
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- PacifiCare HMO
- United Healthcare
- Worker's Compensation WC
Awards
- America's Top Doctors
- Top Doctors:San Diego Area
- America's Top Doctors for Cancer
- Top Doctors:Southern California
- CMS Meaningful Use Stage 1 Certification
- Elected Member
- Super Doctor
Education
-
Stanford University -
Harvard Medical School
Hospital
-
UC San Diego Health
Drug Facts
| NPI NUMBER | 1306861950 | |
| NPPES Provider LastName | KIPPS | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 920931503 | |
| NPPES Provider State | CA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 87.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1306861950 |
| Last Name Of The Provider | KIPPS |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Lyudmila A. Bazhenova, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Huan-You Wang, MD |
|
|
Dr. Richard B. Schwab, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carolyn M. Mulroney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey W. Andrey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederick E. Millard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michelle Phillips, MD |
|
|
Dr. Michael Quigley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina A. To, MD |